Ontology highlight
ABSTRACT: Introduction
Enzalutamide and abiraterone acetate plus prednisolone (AAP) are used in combination with androgen-deprivation therapy to further suppress the androgen stimulation of metastatic castration-resistant prostate cancer (mCRPC). First-line mCRPC treatment with enzalutamide and AAP yields similar overall survival and radiographic progression-free survival in phase III trials. Thus, treatment selection relies on patient choice, cost and side effects. The aim of this randomised trial is to investigate differences in fatigue, health-related quality of life (HRQoL) and metabolic side effects in men with mCRPC treated with first-line enzalutamide versus AAP.Methods and analysis
In this ongoing open-label randomised (1:1) clinical trial, enzalutamide is compared with AAP a
SUBMITTER: Kvorning Ternov K
PROVIDER: S-EPMC6747677 | biostudies-literature | 2019 Sep
REPOSITORIES: biostudies-literature